Literature DB >> 19406470

Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma.

I Aladzsity1, M Kovács, A Semsei, A Falus, A Szilágyi, I Karádi, G Varga, G Füst, J Várkonyi.   

Abstract

The serum levels of interleukin 6 (IL6) are known to be elevated in two diseases of the elderly age, myelodysplastic syndrome (MDS) and multiple myeloma (MM). Authors suppose that one of the possible causes of this elevation could be a difference between these patients and healthy subjects in the frequency of polymorphic variants of the genes regulating IL6 levels. Scarce and contradictory comparative data are available for MM and to our best knowledge this is the first study on IL6 promoter and IL6 receptor (IL6R) polymorphism in MDS. Therefore we determined the Asp358Ala polymorphism of the IL6 receptor gene and the -174 G>C promoter polymorphism of the IL6 gene in blood samples of 102 MDS and 100 MM patients and 99 age- and sex-matched hospitalized controls had been tested for this purpose as well. There was no significant difference between patients with either disease and controls regarding IL6 promoter/L-6R. Authors therefore assume other mechanisms causing high IL6 levels are not related to either of these polymorphisms. Moreover authors consider important to propose a hypothesis how elements of signal transduction in iron metabolism might be involved in the development of MM and MDS in elderly age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406470     DOI: 10.1016/j.leukres.2009.03.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Genetic polymorphisms and multiple myeloma risk: a meta-analysis.

Authors:  Pengcheng Zhang; Bing Liu
Journal:  Ann Hematol       Date:  2020-03-11       Impact factor: 3.673

3.  IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls.

Authors:  Bin Xu; Xiao-Bing Niu; Zi-Dun Wang; Wei Cheng; Na Tong; Yuan-Yuan Mi; Zhi-Chao Min; Jun Tao; Peng-Chao Li; Wei Zhang; Hong-Fei Wu; Zheng-Dong Zhang; Zeng-Jun Wang; Li-Xin Hua; Ning-Han Feng; Xin-Ru Wang
Journal:  Mol Biol Rep       Date:  2010-11-23       Impact factor: 2.316

4.  Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer.

Authors:  Esra Çil; Alkın Kumral; Müge Kanmaz-Özer; Pervin Vural; Semra Doğru-Abbasoğlu; Yüksel Altuntaş; Müjdat Uysal
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

5.  Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization.

Authors:  Geng Tian; Jia Mi; Xiaodan Wei; Dongmei Zhao; Lingyan Qiao; Chunhua Yang; Xianglin Li; Shuping Zhang; Xuri Li; Bin Wang
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

6.  Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis.

Authors:  Xingchun Peng; Jun Shi; Wanqun Sun; Xuzhi Ruan; Yang Guo; Lunhua Zhao; Jue Wang; Bin Li
Journal:  Oncotarget       Date:  2018-01-05

7.  Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk.

Authors:  Md Harun-Or-Roshid; Md Borqat Ali; Md Nurul Haque Mollah
Journal:  PLoS One       Date:  2021-03-08       Impact factor: 3.752

8.  Association between interleukin gene polymorphisms and multiple myeloma susceptibility.

Authors:  Muhamaad Naveed Shahzad; Iqra Ijaz; Syed Shah Zaman Haider Naqvi; Cheng Yan; Fanli Lin; Shutan Li; Chunlan Huang
Journal:  Mol Clin Oncol       Date:  2020-01-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.